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ABSTRACT
Background. Uromodulin, a tissue-specific tubular glycoprotein, has recently emerged as a promising biomarker for kidney
function and tubular integrity. However, the association of serum uromodulin (sUmod) with renal function decline is still
unknown in an older general population.
Methods. We analysed the association of sUmod with the estimated glomerular filtration rate (eGFR) and albuminuria in 1075
participants of the population-based Cooperative Health Research in the Region of Augsburg (KORA) F4 study, ages
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62–81 years, at baseline and prospectively after a mean follow-up time of 6.5 years (n¼605) using logistic and linear
regression models as well as receiver operating characteristics (ROC) analyses.
Results. Cross-sectionally, sUmod was positively associated with eGFR (b¼0.31 6 0.02 per higher standard deviation sUmod;
P<0.001) and inversely associated with the urinary albumin:creatinine ratio (b¼0.19 6 0.04; P<0.001) after adjustment for
sex, age, body mass index, arterial hypertension, prediabetes and diabetes. After multivariable adjustment including
baseline eGFR, sUmod was not associated with incident chronic kidney disease (CKD), defined as a decrease in eGFR
<60 mL/min/1.73 m2 after 6.5 years of follow-up fodds ratio [OR] 1.02 [95% confidence interval (CI) 0.77–1.36] per higher SD
sUmodg but was inversely associated with advanced CKD, defined as incident eGFR <45 mL/min/1.73 m2 [OR 0.64 (95% CI
0.42–0.98)]. The ROC showed no added predictive value of sUmod for kidney function decline in the fully adjusted model.
Conclusions. Higher sUmod was inversely associated with progression to advanced kidney disease but does not provide
additional predictive value for the development of CKD in elderly participants of the population-based KORA study.
Keywords: albuminuria, eGFR, general community, serum uromodulin
INTRODUCTION
Uromodulin is a glycosylphosphatidylinositol-anchored protein
synthesized in tubular cells of the ascending limb of Henle’s
loop and released into the urine by proteolytic cleavage [1–3].
In the urinary tract, the renal defensin uromodulin exerts
anti-lithogen, anti-infective and immunomodulatory functions
[4–11]. Mutations of the uromodulin-coding gene may cause se-
vere kidney damage, such as tubulocystic kidney disease, recur-
ring urinary tract infections, familial juvenile hyperuraemic
nephropathy and congenital nephrolithiasis [3, 6, 8, 12–14]. Even
small changes in uromodulin concentration or function, e.g.
caused by uromodulin loci variants, may trigger or accelerate
kidney disease [15–21]. In addition, inflammatory, ischaemic or
toxic kidney disease with the loss of epithelia releasing uromo-
dulin might aggravate the kidney function decline [22, 23].
Due to active secretion from the basolateral side of tubular
cells into the interstitial space and circulation, uromodulin is
also present in the bloodstream [24–26]. Serum uromodulin
(sUmod) is a promising kidney tissue biomarker [25–28] that
does not directly depend on glomerular filtration but mirrors tu-
bular function and nephron mass [29, 30].
A positive association of sUmod with kidney function has
been shown in patients with chronic kidney disease (CKD) [25,
26, 31], after kidney transplantation [25], in patients admitted
for coronary angiography [27, 28] and in healthy individuals of
different age groups [25, 32]. Longitudinal evaluations are only
available in preselected cohorts involving patients with coro-
nary and/or renal disease, in which sUmod is inversely related
to kidney function decline [27, 31]. The association of sUmod
with renal outcome in older populations from the general com-
munity is still unknown. Older people deserve special attention
when evaluating kidney function because estimated glomerular
filtration rate (eGFR) based on serum creatinine may be unreli-
able due to variable muscle mass losses, including sarcopenia.
Additionally, comorbidities influencing eGFR via hyperfiltration,
such as diabetes, obesity and arterial hypertension, accumulate
in older age groups. Subsequently, episodes of unforeseen acute
kidney failure become more frequent and correct drug dosing
may be challenging [33]. Therefore the validation of a comple-
mentary kidney tissue marker not directly depending on eGFR
is especially crucial for older people. Recently it has been shown
that independent of eGFR, sUmod is inversely associated with
type 2 diabetes, obesity and metabolic syndrome and its single
components, including elevated blood pressure [34–36], provid-
ing the rationale to assume that sUmod might be a promising
candidate biomarker for kidney function in an elderly general
population typically having a high frequency of these risk fac-
tors. We here investigated the association of sUmod with kid-
ney function cross-sectionally and longitudinally in elderly
participants of the population-based Cooperative Health
Research in the Region of Augsburg (KORA) F4/FF4 cohort. The
hypothesis was that the results obtained from cohorts including
patients with CKD and/or coronary heart disease showing an in-
verse association of sUmod with kidney function decline are
transferable to our older population-based cohort and that




The KORA F4 (2006–08) and FF4 (2013–14) studies are follow-up
examinations of the population-based KORA S4 study (1999–
2001) in southern Germany. Recruitment and eligibility criteria,
study design, standardized sampling methods and data collec-
tion (medical history, medication, anthropometric measure-
ments and blood pressure) have been described previously [37–
39]. All study participants gave written informed consent. The
study was approved by the Ethics Committees of the Bavarian
Medical Association in adherence with the Declaration of
Helsinki. sUmod was measured in 1119 participants ages
62–81 years of the KORA F4 study with available serum samples
(from a total of 1161 participants in this age group). All variables
required for the cross-sectional analyses were available in 1075
participants. Of these 1075 participants, 119 died and 336 could
not be contacted or declined to take part in the FF4 follow-up
examination. Thus the study sample for the FF4 examination
comprised 620 participants, of which 15 had to be excluded
due to missing covariables (Supplementary data, Figure S1).
The mean follow-up period was 6.5 6 0.3 years.
Clinical diagnosis of diabetes mellitus was based on a vali-
dated physician’s diagnosis or the current use of glucose-
lowering agents. After overnight fasting of at least 8 h, all partic-
ipants without clinically diagnosed diabetes underwent a stan-
dard 75-g oral glucose tolerance test. Newly diagnosed diabetes,
impaired glucose tolerance (IGT), impaired fasting glucose (IFG)
and normal glucose tolerance were defined according to the
American Diabetes Association diagnostic criteria based on
both fasting and post-challenge glucose values (type 2 diabetes:
7.0 mmol/L fasting and/or 11.1 mmol/L 2-h glucose; IFG:
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5.6 mmol/L and <7.0 mmol/L fasting glucose; IGT: 7.8–
<11.1 mmol/L 2-h glucose). Prediabetes was defined as IFG and/
or IGT (2-h glucose 7.8–<11.1 mmol/L). Participants with a
diabetes type other than type 2 diabetes (n¼ 3) or unclassified
glucose tolerance status (n¼ 22) were excluded. Arterial hyper-
tension was defined as systolic blood pressure 140 mmHg,
diastolic blood pressure 90 mmHg or known hypertension
with the use of antihypertensive drugs.
Laboratory measurements
Blood was kept at room temperature until centrifugation.
Plasma and serum samples were assayed immediately or stored
at 80C. Measurements of serum creatinine, cystatin C and
glucose were performed as described elsewhere [40]. Urinary
creatinine concentration (Jaffe method) was determined on a
Cobas Mira chemistry analyser (Greiner, Bahlingen, Germany).
Urinary albumin concentration was measured with an immu-
noturbidimetric test (Tina-quant_Albumin in urine, Boehringer
Mannheim, Germany) from a single-spot urine sample that had
been stored at 80 C. sUmod was measured as described previ-
ously [26] using a commercial enzyme-linked immunosorbent
assay kit (Euroimmun, Lübeck, Germany) with a lower detection
limit of 2 ng/mL, an intra-assay coefficient of variation of 2.3%
and interassay coefficients of variation of 4.4 and 9.5% for
sUmod target values of 24.9 and 142.2 ng/mL, respectively. eGFR
was calculated using the Chronic Kidney Disease Epidemiology
Collaboration equation based on both serum creatinine and cys-
tatin C [41].
Statistical analyses
The analyses were performed using the statistical environment
R, version 3.6.2 (R Foundation, Vienna, Austria). The level of sta-
tistical significance was set at 5% (two-sided). Characteristics of
the study participants were compared between sUmod quartiles
using the Kruskal–Wallis test in the case of approximately nor-
mally distributed variables. For skewed distributed variables,
analysis of variance tests were performed. Binomial proportions
were compared with chi-squared tests. Spearman’s rank test
was used to assess the correlation of untransformed sUmod
and eGFR and Pearson’s correlation coefficient was used to ana-
lyse the correlation of logarithmized sUmod with eGFR. In the
regression models, sUmod [log-transformed, continuous per
standard deviation [SD]) was used as an exposure variable. eGFR
categories, albuminuria and albuminuria categories were
employed as outcome variables. The associations of sUmod
with eGFR and albuminuria as continuous variables were
assessed in linear regression models. The associations of
sUmod with categorical variables were investigated using logis-
tic regression models. The results are given as odds ratio [95%
confidence interval (CI)] or standardized b coefficient 6 stan-
dard error (SE), respectively. In multivariable logistic and linear
regression analyses, the models were adjusted for the covari-
ates sex, age, body mass index (BMI), arterial hypertension, pre-
diabetes/type 2 diabetes and baseline eGFR (in the longitudinal
analyses). The association of sUmod with albuminuria was ad-
justed for eGFR. The models are indicated in the tables for each
analysis. Receiver operating characteristics (ROC) analyses were
performed to investigate the predictive value of sUmod for inci-
dent CKD using the R package pROC (R Foundation).
RESULTS
Study population characteristics
The characteristics of the study population stratified by sUmod
quartiles are presented in Table 1. The higher sUmod quartiles
showed a more favourable metabolic and cardiovascular risk
profile as well as higher eGFR values as compared with the
lower sUmod quartiles.
Cross-sectional association of sUmod with eGFR
sUmod correlated with eGFR (Supplementary data, Figure S2).
The relationship of untransformed sUmod with eGFR was fairly
linear in the lower ranges of both parameters (Supplementary
data, Figure S2B). However, at an eGFR >74 mL/min/1.73 m2, the
relation of the eGFR and untransformed sUmod was not signifi-
cant due to the large variation in sUmod values in the higher
ranges. Logarithmized sUmod displayed a linear relation with
eGFR (Supplementary data, Figure S2C).
sUmod was lower in participants with prevalent kidney dis-
ease. The median sUmod was 183.8 ng/mL (first quartile 141.2,
third quartile 242.1) in study participants with an eGFR 90 mL/
min/1.73 m2, 158.6 (115.8–210.3) in participants with an eGFR of
60–89 mL/min/1.73 m2, 112.2 (83.9–132.7) in participants with an
eGFR of 45–59 mL/min/1.73 m2 and 75.2 (46.4–99.4) in partici-
pants with an eGFR <45 mL/min/1.73 m2. sUmod was also sig-
nificantly positively associated with the eGFR in the linear
regression models (Table 2). In line with these findings, multi-
variable logistic regression analyses revealed an inverse associ-
ation of sUmod with a categorized eGFR <90, <60 and <45 mL/
min/1.73 m2 in all models (Supplementary data, Table S1).
Longitudinal association of sUmod with change in eGFR
Baseline sUmod was not associated with DeGFR (change in eGFR
from baseline to the follow-up examination) in the crude model
(b¼0.02 6 0.05) or in the model adjusted for sex, age, BMI, hy-
pertension and prediabetes/type 2 diabetes (b¼ 0.004 6 0.04).
Higher baseline sUmod was related to a lower incidence of
eGFR <60 mL/min/1.73 m2 after adjustment for sex, age, BMI, hy-
pertension and prediabetes/type 2 diabetes, but this association
disappeared after additional adjustment for baseline eGFR.
sUmod remained significantly inversely associated with an inci-
dent eGFR <45 mL/min/1.73 m2 after multivariable adjustment
(Table 3).
ROC analysis (Figure 1) showed no added predictive value of
sUmod for incident eGFR <60 mL/min/1.73 m2 [area under the
curve 0.86 (95% CI 0.82–0.89) for both the base model including
baseline eGFR, sex, age, BMI, arterial hypertension and predia-
betes/diabetes and the model including sUmod]. For an incident
eGFR <45 mL/min/1.73 m2, adding sUmod to the base model in-
creased the area under the curve from 0.88 (95% CI 0.83–0.92) to
0.89 (95% CI 0.84–0.93), which was not significant (P¼ 0.20).
Regarding the urinary albumin:creatinine ratio as a known
predictor of kidney function, adding sUmod to the ROC model
provided no additional predictive value for an incident eGFR
<60 mL/min/1.73 m2 [area under the curve 0.75 (95% CI 0.70–
0.79)] compared with the base model including the urinary albu-
min:creatinine ratio, sex, age, BMI, arterial hypertension and
prediabetes/diabetes [area under the curve 0.74 (95% CI 0.69–
0.79), P¼ 0.37; Figure 1C]. For an incident eGFR <45 mL/min/
1.73 m2, the area under the curve was higher in the model in-
cluding sUmod [0.83 (95% CI 0.78–0.87)] compared with the base
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model [0.79 (95% CI 0.73–0.86)]. However, this difference was not
statistically significant (P¼ 0.053; Figure 1D).
Association of sUmod with albuminuria
sUmod was inversely associated with the urinary
albumin:creatinine ratio as a continuous variable and with a
urinary albumin:creatinine ratio 30 mg/g after multivariable
adjustment including eGFR (P< 0.001; Supplementary data,
Table S2).
Baseline sUmod was inversely associated with the evolu-
tion of a urinary albumin:creatinine ratio 30 mg/g in the
crude longitudinal analysis (P< 0.001), but the association
was no longer significant after multivariable adjustment
(Supplementary data, Table S2).
DISCUSSION
We analysed the association of sUmod with kidney function at
baseline and with the development of kidney disease during
follow-up in a community-based population. sUmod was
strongly associated with eGFR in the cross-sectional analysis.
Table 1. Baseline characteristics of study participants
Parameter All participants sUmod Q1 sUmod Q2 sUmod Q3 sUmod Q4 P-value
n 1075 269 269 268 269 –
sUmod (ng/mL), mean 6 SD 152.5 (110.0–207.7) 84.8 (64.9–96.6) 129.8 (120.7–141.0) 177.1 (166.3–190.9) 248.2 (224.9–281.8) –
Sex (female), n (%) 528 (49) 108 (40) 116 (43) 135 (50) 169 (63) <0.001a
Age (years), mean 6 SD 70.2 6 5.5 71.8 6 5.7 70.8 6 5.6 69.7 6 5.3 68.8 6 4.8 <0.001b
BMI (kg/m2), mean 6 SD 28.7 6 4.5 29.7 6 4.8 29.2 6 4.7 28.6 6 4.0 27.4 6 4.1 <0.001b
Arterial hypertension, n (%) 669 (62) 202 (75) 184 (68) 152 (57) 131 (49) <0.001a
Type 2 diabetes, n (%) 213 (20) 82 (30) 59 (22) 48 (18) 24 (9) <0.001a
HbA1c (mmol/mol) 37.7 (35.5–41.0) 38.8 (36.6–43.2) 38.8 (36.6–41.0) 37.7 (35.5–41.0) 37.7 (34.4–39.9) <0.001c
eGFR (mL/min/1.73 m2), mean 6 SD 76.4 6 15.7 67.9 6 18.4 74.4 6 14.0 80.2 6 12.8 83.2 6 11.5 <0.001a
Urinary albumin:
creatinine ratio (mg/g)
8.4 (4.7–17.6) 12.4 (6.4–32.4) 7.9 (4.4–15.9) 7.5 (4.5–13.7) 6.8 (4.3–12.7) <0.001c
Urinary albumin:
creatinine ratio 30 mg/g, n (%)






Analysis of variance test.
Value presented as median (first quartile–third quartile) unless stated otherwise.
Table 2. Association estimates between sUmod and baseline eGFR as
continuous variables: b coefficients 6 standard error from linear re-
gression models are given per SD sUmod (logarithmized) (n¼1075)
eGFR P-value
Without adjustment
0.384 6 0.023 <0.001
Adjustment for sex, age, BMI, arterial hypertension and
prediabetes/type 2 diabetes
0.305 6 0.022 < 0.001
Table 3. ORs (95% CIs) for incident CKD per SD sUmod (logarith-
mized): results of logistic regression models
Incident eGFR
<60 mL/min/1.73 m2 P-value
Incident eGFR
<45 mL/min/1.73 m2 P-value
Yes: n¼ 126; no: n¼ 425 Yes: n¼ 50;
no: n¼544
Without adjustment
0.73 (0.59–0.91) 0.005 0.44 (0.33–0.61) <0.001
Adjustment for sex, age, BMI, arterial hypertension and
prediabetes/diabetes
0.76 (0.59–0.98) 0.032 0.47 (0.33–0.67) <0.001
Adjustment for sex, age, BMI, arterial hypertension,
prediabetes/diabetes and baseline eGFR
1.02 (0.77–1.36) 0.890 0.64 (0.42–0.98) 0.038 FIGURE 1: ROC analyses for the predictive value of sUmod for incident eGFR
<60 mL/min/1.73 m2 (A and C) and incident eGFR <45 mL/min/1.73 m2 (B and D).
Black: base model including sex, age, BMI, arterial hypertension, prediabetes/di-
abetes and baseline eGFR; blue: base model including sex, age, BMI, arterial hy-
pertension, prediabetes/diabetes and baseline urinary albumin:creatinine ratio
and red: respective base model plus sUmod.






/ckj/article/14/1/205/5827727 by guest on 22 February 2021
These results are in agreement with previous studies assessing
different study populations [25–28]. In incipient kidney damage,
the uromodulin decrease may precede the eGFR decline, since a
progressive nephron loss may initially be compensated for
by increased hydraulic pressure and subsequent glomerular
hyperfiltration [25, 26]. Hence uromodulin is a promising
marker for decreased kidney function already in the early stages
and in primarily tubular injury. Since uromodulin is indepen-
dent of glomerular hyperfiltration, it may be an interesting
marker for early kidney disease in diabetes and other states in
which eGFR may be disproportionately high due to hyperfiltra-
tion [26]. In line with this, we and others have shown that
sUmod levels are decreased in type 2 diabetes independent of
eGFR [34, 35]. Furthermore, sUmod was associated with protein-
uria in the study of Steubl et al. [26] and with albuminuria in our
cohort, suggesting that sUmod may, in fact, be a marker for
early prevalent diabetic kidney disease.
In our longitudinal analysis, however, baseline sUmod was
not associated with a decline of eGFR <60 mL/min/1.73 m2 and
did not improve the prediction of kidney function decline in the
ROC analysis. These results are in contrast with previous
studies assessing the association of uromodulin with renal out-
comes. However, these studies used urinary uromodulin and/or
were performed in selected cohorts mainly involving partici-
pants with pre-existing CKD. The Framingham Heart Study
showed an association of higher urinary uromodulin with a re-
duced risk of kidney disease progression [15]. In the Health ABC
Study, urinary uromodulin was inversely associated with inci-
dent CKD [42]. In patients with CKD, low sUmod was associated
with a higher risk of progression to end-stage renal disease [31]
and was a marker of graft failure in recipients of kidney allog-
rafts [43]. Finally, sUmod was decreased in patients admitted
for coronary angiography who developed CKD during follow-up
[27]. This study of Leiherer et al. [27] was smaller and shorter
than our study (529 participants at baseline and 340 participants
at the follow-up examination after 3.5 years). Furthermore, in
the multivariable models, the effect of sUmod on the decline
of eGFR was adjusted for the rs13335818 genotype, which
strengthened the association of sUmod with incident eGFR
<60 mL/min/1.73 m2. Adjusted models without correction for
the genotype were not given. However, for the potential use
of sUmod as a commonly available biomarker in a broader
population, correction for the interaction with genotypes is not
feasible.
Our results are in line with the available literature in so far
as sUmod was associated with a decline of eGFR <45 mL/min/
1.73 m2 in our cohort, indicating that sUmod might be of addi-
tional informative value in more advanced kidney disease only.
Very recently, Steubl et al. [44] described an inverse association
of sUmod with incident end-stage renal disease in 933 partici-
pants of the Cardiovascular Health Study with a mean age of
78 years. This study differed from our population in several
aspects. Corresponding to the higher age, baseline eGFR (63 ver-
sus 76 mL/min/1.73 m2) and sUmod (mean 127.2 versus 162.7 ng/
mL) were lower in participants of the Cardiovascular Health
Study compared with the KORA population and the albumin:-
creatinine ratio (13.9 versus 8.4 mg/g) and systolic blood pres-
sure (137 versus 128 mmHg) were higher, indicating an adverse
risk profile. Still, despite the higher risk profile and the lower
eGFR and sUmod values, sUmod did not predict a decline of kid-
ney function in higher eGFR ranges in this cohort, which is in
line with our results.
The lacking association of sUmod with kidney function
decline in higher eGFR ranges matches the attenuated
cross-sectional correlation of sUmod with eGFR in preserved
kidney function. Whereas uromodulin secretion decreases with
a substantial reduction of total nephron mass, explaining the
strong association with eGFR in the lower ranges, in normal or
near-normal kidney function, other factors influencing uromo-
dulin secretion may become more relevant and might explain
the loss of a direct association of sUmod with kidney function
as measurable by eGFR. For example, sUmod values are higher
in women than in men, indicating that, for example, hormonal
factors may play a role [34]. Furthermore, genetic variations
may influence uromodulin levels in normal kidney function
more strongly than the differences in renal reserve and thus in-
fluence the association of sUmod with incident kidney disease
as demonstrated by Leiherer et al. [27], in whose study sUmod
was only associated with incident kidney disease in the group
homozygous for the rs13335818 major allele. In addition, reac-
tive increases of uromodulin secreted by each functioning
nephron unit may balance the total uromodulin amount in
early kidney disease with sufficiently preserved tubular func-
tion [45]. The stronger inverse association with more advanced
renal disease may derive from an already reduced renal tubular
reserve after substantial kidney damage predisposing to pro-
gressive kidney function loss.
Study limitations and strengths
Our study included Caucasians ages 62–81 years. The associa-
tion of sUmod with renal outcomes remains to be investigated
in younger populations and other ethnicities. Due to the
population-based design, the participants were relatively
healthy and at low risk for the development of kidney disease,
and only a few participants suffered from CKD Stage 4 or higher.
Therefore our study was not suitable to evaluate the association
of sUmod with end-stage renal disease. The major strength of
our study is the large, well-characterized, community-based co-
hort representing a typical older European population and the
follow-up time of 6.5 years. We measured sUmod with a sensi-
tive and robust enzyme-linked immunosorbent assay. In con-
trast to uromodulin of urine origin used in most previous
studies, which forms various polymers with chancing epitopes
and different antigenic sites [46], sUmod is a stable antigen lack-
ing such important pre-analytical disadvantages [26].
CONCLUSIONS
The current study confirms a strong cross-sectional association
of sUmod with kidney function in older participants from a
large population-based study. However, sUmod did not provide
additional predictive value for kidney function decline beyond
other known risk factors in our population-based cohort, indi-
cating that the results obtained in cohorts with CKD and/or cor-
onary heart disease are not readily transferable to a general
population. Nevertheless, sUmod may be a useful independent
biomarker for the identification of individuals at risk for the
development of advanced kidney disease.
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